

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT2819839

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
PREDICTIVE BIOSCIENCES, INC.	04/01/2014
RECEIVING PARTY DATA	
Name:	PHYSICIANS CHOICE LABORATORY SERVICES, LLC
Street Address:	854 PARAGON WAY
City:	ROCK HILL
State/Country:	SOUTH CAROLINA
Postal Code:	29730
PROPERTY NUMBERS Total: 26	
Property Type	Number
Application Number:	11840777
Application Number:	13472366
Application Number:	12034698
Application Number:	12774303
Application Number:	12819700
Application Number:	13018553
Application Number:	13161074
Application Number:	13868666
Application Number:	13489209
Application Number:	13960121
Application Number:	12120544
Application Number:	13559308
Application Number:	12689542
Application Number:	12689597
Application Number:	13472209
Application Number:	13770646
Application Number:	13770663
Application Number:	13857753
Application Number:	13364840
Application Number:	13472262
Application Number:	13741183

PATENT

Property Type	Number
Application Number:	13661666
Application Number:	13757287
Application Number:	13472331
Application Number:	13472334
Application Number:	13472339

CORRESPONDENCE DATA

Fax Number: (336)726-9031

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.

Phone: (336) 721-3681

Email: ethanski@wcsr.com

Correspondent Name: CARL B. MASSEY, JR.

Address Line 1: P.O. BOX 7037

Address Line 4: ATLANTA, GEORGIA 30357

NAME OF SUBMITTER:	CARL B. MASSEY, JR.
SIGNATURE:	/Carl B. Massey, Jr./
DATE SIGNED:	04/17/2014

Total Attachments: 5

source=PCLS Assignment#page1.tif

source=PCLS Assignment#page2.tif

source=PCLS Assignment#page3.tif

source=PCLS Assignment#page4.tif

source=PCLS Assignment#page5.tif

PATENT ASSIGNMENT

WHEREAS, PREDICTIVE BIOSCIENCES, INC., a Delaware corporation (a/k/a Predictive Biosciences Corporation), having a principal place of business at 282 Central Street, Unit 9, Hudson, MA, in care of KallanderGroup, Inc. ("Assignor"), is the 100% owner of various patents and patent applications listed on Schedule A, attached hereto.

WHEREAS, PHYSICIANS CHOICE LABORATORY SERVICES, LLC, a Florida limited liability company, having a principal place of business at 854 Paragon Way, Rock Hill, SC 29730 (Assignee), is desirous of obtaining the entire right, title and interest in, to and under said patents, patent application(s) and invention(s) disclosed therein;

NOW, THEREFORE, in consideration of good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR has sold, assigned, transferred and set over, and by these presents does hereby sell, assign, transfer and set over, unto said ASSIGNEE, its successors, legal representatives and assigns, ASSIGNOR's entire right, title and interest in, to and under said patents, patent applications and inventions, including:

- all rights to sue and recover damages for past infringement thereof;
- all continuations, continuations-in-part, divisionals, reissues, renewals and extensions thereof;
- all patents which may be granted thereon, in any country or countries, and all continuations, divisionals, reissues, renewals and extensions thereof;
- all other forms of industrial property protection, including, without limitation, utility models, inventors' certificates and designs which may be granted thereon in any country or countries, and all continuations, divisionals, reissues, renewals and extensions thereof;
- the right to file new patent applications in any country or countries, and the right to claim for same the priority rights derived from any of the listed patents and patent applications under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, or any other international agreement or the domestic laws of the country in which any such new patent application is filed, as may be applicable;

AND ASSIGNOR HEREBY authorizes and requests any Official of any country or countries, whose duty it is to issue patents or other evidence or forms of industrial property protection on applications as aforesaid, to issue said application to said ASSIGNEE, its successors, legal representatives and assigns, in accordance with the terms of this instrument.

AND ASSIGNOR HEREBY covenants and agrees that it has full right to convey the entire interest herein assigned, and that Assignor has not executed, and will not execute, any agreement in conflict herewith.


AND ASSIGNOR HEREBY further covenants and agrees that it will communicate to said ASSIGNEE, its successors, legal representatives and assigns, any facts known to it respecting said inventions, and, testify in any legal proceeding if ASSIGNEE pays ASSIGNOR'S reasonable expenses, sign all lawful papers, execute all divisional, continuing and reissue applications, make all rightful oaths, and generally do everything reasonably possible to aid the

WCSR 32088768v1


said ASSIGNEE, its successors, legal representatives and assigns, to obtain and enforce proper protection for said inventions.

IN WITNESS WHEREOF, the undersigned has affixed his/her signature in his/her named capacity.


Assignor: Predictive Biosciences, Inc.


By: Barry Kallander
Title: _____

April 1, 2014
Date


Witness _____


4/1/14
Date


Witness _____

4/1/14
Date

IN WITNESS WHEREOF, the undersigned has affixed his/her signature in his/her named capacity, to accept the present Assignment.


Assignee: PHYSICIANS CHOICE LABORATORY SERVICES, LLC


By: Joe Wiegel
Title: President & CEO

4/2/2014
Date


Witness _____

4/2/2014
Date


Witness _____

4/2/2014
Date

WCSR 32088768v1

SCHEDULE A

List of Patent Applications and Patents Assigned

Application No.	Application Date	Title	Country
60/903,838	Feb-23-2007	Clinical Intervention and Directed Diagnosis	US
11/840,777	Aug-17-2007	Clinical Intervention and Directed Diagnosis	US
PCT/US2008/054563	Feb-21-2008	Clinical Intervention and Directed Diagnosis	PCT
08730378.0	Aug-25-2009	Clinical Intervention and Directed Diagnosis	Europe
13/472,366	May-15-2012	Detection of Cancer	US
PCT/US2013/041183	May-15-2013	Detection of Cancer	PCT
10105141.5	May-26-2010	Clinical Intervention and Directed Diagnosis	Hong Kong
509238443	Aug-24-2009	Clinical Intervention and Directed Diagnosis	Japan
2679205	Aug-24-2009	Clinical Intervention and Directed Diagnosis	Canada
60/972,507	Sept-14-2007	Multiple Analyte Diagnostic Readout	US
12/034,698	Feb-21-2008	Multiple Analyte Diagnostic Readout	US
PCT/US2008/076193	Sept-12-2008	Multiple Analyte Diagnostic Readout	PCT
08833219.4	Mar-8-2010	Multiple Analyte Diagnostic Readout	Europe
2010-525032	Mar-11-2010	Multiple Analyte Diagnostic Readout	Japan
2698859	Mar-8-2010	Multiple Analyte Diagnostic Readout	Canada
200880113288.6	Apr-26-2010	Multiple Analyte Diagnostic Readout	China
12/774,303	May-5-2010	Serial Analysis of Biomarkers for Disease Diagnosis	US
PCT/US11/35102	Nov-11-2011	Serial Analysis of Biomarkers for Disease Diagnosis	PCT
11/778230.0	May-4-2011	Serial Analysis of Biomarkers for Disease Diagnosis	EP
2797825	May-4-2011	Serial Analysis of Biomarkers for Disease Diagnosis	CA
12/819,700	June-21-2010	Detection of Nucleic Acids and Proteins	US
PCT/US11/37539	Mar-15-2012	Detection of Nucleic Acids and Proteins	PCT
11/798539.8	May-23-2011	Detection of Nucleic Acids and Proteins	EP
2081305	May-23-2011	Detection of Nucleic Acids and Proteins	CA

WCSR 32088768v1

Application No.	Application Date	Title	Country
13/018,553	Feb-1-2011	Detection of Nucleic Acids and Proteins	US
13/161,074	Jun-15-2011	Detection of Nucleic Acids and Proteins	US
13/868,666	Apr-23-2013	Detection of Nucleic Acids and Proteins	US
13/489,209	June-05-2012	Detection of Nucleic Acids and Proteins	US
PCT/US2013/044294	June-05-2013	Detection of Nucleic Acids and Proteins	PCT
13/960,121	Aug-6-2013	Detection of Nucleic Acids and Proteins	US
60/917,705	May-14-2007	ADAM-12 as a Biomarker for Bladder Cancer	US
12/120,544	May-14-2008	ADAM-12 as a Biomarker for Bladder Cancer	US
13/559,308	Jul-26-2012	ADAM-12 as a Biomarker for Bladder Cancer	US
12/689,542	Jan-19-2010	Antibodies and Use for Disease Diagnosis	US
PCT/US2010/050155	Sept-24-2010	Antibodies and Use for Disease Diagnosis	PCT
12/689,597	Jan-19-2010	Method for Assuring Amplification of an Abnormal Nucleic Acid in a Sample	US
PCT/US2010/050195	Sept-24-2010	Method for Assuring Amplification of an Abnormal Nucleic Acid in a Sample	PCT
10844135.3	Sept-24-2010	Method for Assuring Amplification of an Abnormal Nucleic Acid in a Sample	EP
2012-548931	Sept-24-2010	Method for Assuring Amplification of an Abnormal Nucleic Acid in a Sample	JP
13/472,209	May-15-2012	Primers for Analyzing Methylated Sequences and Methods of Use Thereof	US
13/770,646	Feb-19-2013	Primers for Analyzing Methylated Sequences and Methods of Use Thereof	US
13/770,663	Feb-19-2013	Primers for Analyzing Methylated Sequences and Methods of Use Thereof	US
13/857,753	Apr-05-2013	Primers for Analyzing Methylated Sequences and Methods of Use Thereof	US
PCT/US13/41180	May-15-2013	Primers for Analyzing Methylated Sequences and Methods of Use Thereof	PCT

WCSR 32088768v1

Application No.	Application Date	Title	Country
61/509,898	Jul-20-2011	Methods for Assessing Genomic Instabilities in Tumors	US
13/364,840	Feb-02-2012	Methods for Assessing Genomic Instabilities in Tumors	US
13/472,262	May-15-2012	Methods for Assessing Genomic Instabilities in Tumors	US
PCT/US2013/041176	Nov-21-2013	Methods for Assessing Genomic Instabilities in Tumors	PCT
13/741,183	Jan-14-2013	Methods for Assessing Genomic Instabilities in Tumors	US
PCT/US12/47440	Jul-19-2012	Methods for Assessing Genomic Instabilities in Tumors	PCT
61/552,945	Oct-28-2011	Methods for Detecting Mutations	US
13/661,666	Oct-26-2012	Methods for Detecting Mutations	US
61/594,102	Feb-02-2012	Composite Assay for Detecting a Clinical Condition	US
13/757,287	Feb-01-2013	Composite Assay for Detecting a Clinical Condition	US
PCT/US2013/024439	Feb-1-2013	Composite Assay for Detecting a Clinical Condition	US
13/472,331	Oct-4-2012	Detection of Bladder Cancers	US
PCT/US2013/041194	May-15-2013	Detection of Bladder Cancers	PCT
13/472,334	Sept-27-2012	Detection of Bladder Cancer Recurrence	US
PCT/US2013/041188	May-15-2013	Detection of Bladder Cancer Recurrence	PCT
13/472,339	May-15-2012	Screening for Bladder Cancer	US
PCT/US2013/041186	May-15-2013	Screening for Bladder Cancer	PCT
61/820061	May-6-2013	Diagnostic Assay Combining Cellular and Cell Free Nucleic Acids	US

WCSR 32088768v1